Skip to main navigation Skip to search Skip to main content

Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis

  • Robert T. Jacobs*
  • , Christopher S. Lunde
  • , Yvonne R. Freund
  • , Vincent Hernandez
  • , Xianfeng Li
  • , Yi Xia
  • , David S. Carter
  • , Pamela W. Berry
  • , Jason Halladay
  • , Fernando Rock
  • , Rianna Stefanakis
  • , Eric Easom
  • , Jacob J. Plattner
  • , Louise Ford
  • , Kelly L. Johnston
  • , Darren A.N. Cook
  • , Rachel Clare
  • , Andrew Cassidy
  • , Laura Myhill
  • , Hayley Tyrer
  • Joanne Gamble, Ana F. Guimaraes, Andrew Steven, Franziska Lenz, Alexandra Ehrens, Stefan J. Frohberger, Marianne Koschel, Achim Hoerauf, Marc P. Hübner, Case W. McNamara, Malina A. Bakowski, Joseph D. Turner, Mark J. Taylor, Stephen A. Ward
*Corresponding author for this work
  • Pfizer
  • Liverpool School of Tropical Medicine
  • Department of Parasitology
  • University of Bonn
  • Calibr

Research output: Contribution to journalArticle (journal)peer-review

Abstract

A series of pleuromutilins modified by introduction of a boron-containing heterocycle on C(14) of the polycyclic core are described. These analogs were found to be potent anti-Wolbachia antibiotics and, as such, may be useful in the treatment of filarial infections caused by Onchocerca volvulus, resulting in Onchocerciasis or river blindness, or Wuchereria bancrofti and Brugia malayi and related parasitic nematodes resulting in lymphatic filariasis. These two important neglected tropical diseases disproportionately impact patients in the developing world. The lead preclinical candidate compound containing 7-fluoro-6-oxybenzoxaborole (15, AN11251) was shown to have good in vitro anti-Wolbachia activity and physicochemical and pharmacokinetic properties providing high exposure in plasma. The lead was effective in reducing the Wolbachia load in filarial worms following oral administration to mice.

Original languageEnglish
Pages (from-to)2521-2540
Number of pages20
JournalJournal of Medicinal Chemistry
Volume62
Issue number5
DOIs
Publication statusPublished - 14 Mar 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis'. Together they form a unique fingerprint.

Cite this